October 18, 2021 The pandemic has set ablaze the white-hot market for Digital Therapeutics (DTx), which “deliver medical interventions directly to patients using evidence-based, clinically evaluated software to treat, manage, and prevent a broad spectrum of diseases and disorders.” Read more here.
September 1, 2021 In recent years, there has been a great deal of talk in healthcare circles about remote patient monitoring (RPM), a trend that has only accelerated over the past 18 months with the arrival of COVID-19 and the need, early in the pandemic, to transfer a great deal of care to remote delivery.… Continue reading Misconceptions and Truths about Remote Patient Monitoring
August 31, 2021 In this episode of Medtech Matters, a podcast focused on the medical device manufacturing industry and the factors impacting it, we speak with Russ Johannesson, CEO of Glooko. He speaks about the advantages remote monitoring offers to both physicians of diabetics as well as the patients themselves. Read more here.
June 26, 2021 A study assessing use of remote patient monitoring in patients with type 2 diabetes outlines the impact continued participation in digital monitoring programs can have on glycemic control among this patient population. Read more here.
June 25, 2021 According to study findings presented by Glooko at the American Diabetes Association (ADA) scientific sessions on Friday, remote patient monitoring (RPM) helped patients with type 2 diabetes achieve improved and sustained glycaemic control. Read more here.
June 23, 2021 The company aims to secure a CE mark for the Tempo Smart Button by the end of this year, enabling it and the Tempo Pen to be sold as a single package in European markets. Read more here.
June 5, 2021 Glooko Inc., en ledande leverantör av lösningar för patientövervakning och datahantering på distans för diabetes och andra kroniska tillstånd, meddelade idag att ett strategiskt samarbete har inletts med Eli Lilly… Read more here.
April 30, 2021 To make sure its upcoming connected insulin pen system will work with the user’s choice of daily diabetes management platforms, Eli Lilly & Co. has signed compatibility agreements with four international providers. That includes glucose monitoring sensors, digital health programs and other tools from Roche, Dexcom, Glooko and myDiabby Healthcare. Read more… Continue reading Russ Johannesson on Setting the Pace in Digital Health
April 20, 2021 In 2015, the Clinical Trial Transformation Initiative (CTTI) recommended that trial sponsors consider fully or partially decentralized DCTs, defined as trials executed through telemedicine and mobile/local healthcare providers. Read more here.